Sumitomo Pharma Co., Ltd.'s Form 4 filing
Myovant Sciences Ltd. (MYOV) · filed Sep 3, 2021
- Accession no.
- 0000899243-21-035135
- Filed
- Sep 3, 2021, 5:00 PM ET
- Trade date
- Sep 1-2, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $2.64M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sumitomo Pharma Co., Ltd.CIK 0001446601 | 10% Owner |
| Sumitovant Biopharma Ltd.CIK 0001798244 | 10% Owner |
| Sumitomo Chemical Co., Ltd.CIK 0001798550 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2021 | Common Stock | PPurchaseAcquired | +40,000 | $24.83F2 | +$993,028 | 49,167,776 | Indirect | |
| Sep 2, 2021 | Common Stock | PPurchaseAcquired | +22,209 | $25.25F5 | +$560,872.75 | 49,189,985 | Indirect | |
| Sep 2, 2021 | Common Stock | PPurchaseAcquired | +35,045 | $26.46F7 | +$927,388.83 | 49,225,030 | Indirect | |
| Sep 2, 2021 | Common Stock | PPurchaseAcquired | +5,848 | $26.95F8 | +$157,631.09 | 49,230,878 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades ranging from $24.33 to $24.99 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F5
The transaction was executed in multiple trades ranging from $24.85 to $25.80 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F7
The transaction was executed in multiple trades ranging from $25.90 to $26.89 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F8
The transaction was executed in multiple trades ranging from $26.91 to $27.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.